Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Nov;66(11):2632-42.
doi: 10.1093/jac/dkr344. Epub 2011 Sep 6.

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

Inge C Gyssens  1 , Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolaas Schaper, Barbara Hampel, Peter Reimnitz, Jeff Alder, Pierre Arvis
Affiliations
Randomized Controlled Trial

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

Inge C Gyssens et al. J Antimicrob Chemother. 2011 Nov.

Abstract

Objectives: The primary aim of the RELIEF study was to evaluate the efficacy and safety of two sequential intravenous (iv)/oral regimens: moxifloxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC).

Patients and methods: The study had a prospective, randomized, double-dummy, double-blind, multicentre design. Patients ≥18 years were prospectively stratified according to complicated skin and skin structure infection (cSSSI) subtype/diagnosis (major abscess, diabetic foot infection, wound infection or infected ischaemic ulcer), surgical intervention and severity of illness. Diagnoses and disease severity were based on predetermined criteria, documented by repeated photographs, and confirmed by an independent data review committee. Patients were randomized to receive either 400 mg of moxifloxacin iv once daily followed by 400 mg of moxifloxacin orally once daily or 4.0/0.5 g of TZP iv thrice daily followed by 875/125 mg of AMC orally twice daily for 7-21 days. The primary efficacy variable was clinical response at test of cure (TOC) for the per-protocol (PP) population. Clinical efficacy was assessed by the data review committee based on repeated photographs and case descriptions. Clinical trials registry number: NCT 00402727.

Results: A total of 813 patients were randomized. Clinical success rates at TOC were similar for moxifloxacin and TZP-AMC in the PP [320/361 (88.6%) versus 275/307 (89.6%), respectively; P = 0.758] and intent-to-treat (ITT) [350/426 (82.2%) versus 305/377 (80.9%), respectively; P = 0.632] populations. Thus, moxifloxacin was non-inferior to TZP-AMC. Bacteriological success rates were high in both treatment arms [moxifloxacin: 432/497 (86.9%) versus TZP-AMC: 370/429 (86.2%), microbiologically valid (MBV) population]. Moxifloxacin was non-inferior to TZP-AMC at TOC in both the MBV and the ITT populations. Both treatments were well tolerated.

Conclusions: Once-daily iv/oral moxifloxacin monotherapy was clinically and bacteriologically non-inferior to iv TZP thrice daily followed by oral AMC twice daily in patients with cSSSIs.

Trial registration: ClinicalTrials.gov NCT00402727.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient flow through the study.
Figure 2.
Figure 2.
Clinical success at TOC (PP and ITT populations).
See this image and copyright information in PMC

References

    1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53(Suppl S2):ii37–50. doi:10.1093/jac/dkh202. - DOI - PubMed
    1. CDC. Soft tissue infections among injection drug users – San Francisco, California, 1996–2000. MMWR. 2001;50:381–4. - PubMed
    1. Giordano P, Song J, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin–tazobactam followed by oral amoxicillin–clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26:357–65. doi:10.1016/j.ijantimicag.2005.07.017. - DOI - PubMed
    1. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44:19–23. doi:10.1093/jac/44.suppl_1.19. - DOI - PubMed
    1. Lipsky BA, Weigelt JA, Gupta V, et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. J Antimicrob Chemother. 2007;60:370–6. doi:10.1093/jac/dkm130. - DOI - PubMed

Publication types

MeSH terms

Associated data